JP Morgan Chase’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-21,029
| Closed | -$47.9K | – | 7769 |
|
|
2024
Q2 | $47.9K | Sell |
21,029
-33,605
| -62% | -$128K | ﹤0.01% | 5880 |
|
|
2024
Q1 | $236K | Buy |
54,634
+54,384
| +21,754% | +$190K | ﹤0.01% | 5264 |
|
|
2023
Q4 | $763 | Sell |
250
-9,110
| -97% | -$17.1K | ﹤0.01% | 6873 |
|
|
2023
Q3 | $13.5K | Sell |
9,360
-2,106,513
| -100% | -$4.08M | ﹤0.01% | 6176 |
|
|
2023
Q2 | $5.27M | Sell |
2,115,873
-33,653
| -2% | -$91.9K | ﹤0.01% | 2817 |
|
|
2023
Q1 | $5.76M | Buy |
2,149,526
+113,904
| +6% | +$547K | ﹤0.01% | 2713 |
|
|
2022
Q4 | $11.1M | Sell |
2,035,622
-8,151
| -0.4% | -$68.3K | ﹤0.01% | 2163 |
|
|
2022
Q3 | $25.5M | Sell |
2,043,773
-85,676
| -4% | -$979K | ﹤0.01% | 1415 |
|
|
2022
Q2 | $10.5M | Buy |
2,129,449
+31,696
| +2% | +$176K | ﹤0.01% | 2116 |
|
|
2022
Q1 | $15.9M | Sell |
2,097,753
-45,931
| -2% | -$436K | ﹤0.01% | 1958 |
|
|
2021
Q4 | $21.9M | Sell |
2,143,684
-95,995
| -4% | -$1.22M | ﹤0.01% | 1752 |
|
|
2021
Q3 | $30.1M | Buy |
2,239,679
+363,519
| +19% | +$5.92M | ﹤0.01% | 1472 |
|
|
2021
Q2 | $41.2M | Buy |
1,876,160
+48,271
| +3% | +$1.07M | ﹤0.01% | 1315 |
|
|
2021
Q1 | $44M | Buy |
1,827,889
+159,467
| +10% | +$3.71M | 0.01% | 1217 |
|
|
2020
Q4 | $30M | Buy |
1,668,422
+4,241
| +0.3% | +$63.4K | ﹤0.01% | 1340 |
|
|
2020
Q3 | $19.8M | Sell |
1,664,181
-381,527
| -19% | -$6.3M | ﹤0.01% | 1497 |
|
|
2020
Q2 | $49.6M | Buy |
2,045,708
+349,889
| +21% | +$5.79M | 0.01% | 885 |
|
|
2020
Q1 | $18.7M | Buy |
1,695,819
+26,680
| +2% | +$498K | ﹤0.01% | 1301 |
|
|
2019
Q4 | $44.1M | Buy |
1,669,139
+423,954
| +34% | +$9.91M | 0.01% | 1033 |
|
|
2019
Q3 | $28.4M | Sell |
1,245,185
-183,953
| -13% | -$5.8M | 0.01% | 1330 |
|
|
2019
Q2 | $44.4M | Buy |
1,429,138
+310,614
| +28% | +$6.54M | 0.01% | 1031 |
|
|
2019
Q1 | $18.6M | Buy |
1,118,524
+89,450
| +9% | +$1.7M | ﹤0.01% | 1593 |
|
|
2018
Q4 | $19.7M | Buy |
1,029,074
+498,095
| +94% | +$18.7M | ﹤0.01% | 1504 |
|
|
2018
Q3 | $27.8M | Buy |
530,979
+75,690
| +17% | +$4.13M | 0.01% | 1403 |
|
|
2018
Q2 | $19.8M | Buy |
455,289
+233,734
| +105% | +$10M | ﹤0.01% | 1591 |
|
|
2018
Q1 | $8.21M | Buy |
221,555
+205,881
| +1,314% | +$5.49M | ﹤0.01% | 2164 |
|
|
2017
Q4 | $311K | Buy |
+15,674
| New | +$337K | ﹤0.01% | 4271 |
|
JP Morgan Chase's GTHX Position: Q3 2024 in Review
JP Morgan Chase sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 21,029 shares — an estimated $47.9K sold.
JP Morgan Chase first reported a position in GTHX in Q4 2017 and held it in 27 quarters. The position peaked at $49.6M in Q2 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- JP Morgan Chase reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- JP Morgan Chase sold 21,029 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $47.9K.
- JP Morgan Chase first reported a position in G1 Therapeutics, Inc. Common Stock in Q4 2017 and held it in 27 quarters.
- JP Morgan Chase's G1 Therapeutics, Inc. Common Stock position peaked at $49.6M in Q2 2020.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on JP Morgan Chase's 13F filing for Q3 2024, filed 8 Nov 2024.